Fosun International Ltd

Fosun International held its 2026 interim results presentation in Hong Kong on August 28, marking its first such event in the city in six years. The company reported total revenue of RMB86.96 billion for the first half, with profit attributable to owners of the parent surging 160.3% year-on-year to RMB1.72 billion. Overseas revenue reached RMB49.16 billion, accounting for 56.5% of total revenue. Chairman Guo Guangchang attributed the results to strategic adjustments, including "repairing the roof on a sunny day," and said the company will focus on industries where it holds competitive advantages. The four core companies—Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and the Tourism segment—contributed 73.5% of total revenue. Technology innovation investment rose 16.7% to RMB4.2 billion. The board maintains a medium-term target of restoring annual profit to the RMB10 billion level.

Club Med Lifestyle Group, a subsidiary of Fosun International Limited, has submitted a listing application to the Hong Kong Stock Exchange for a proposed separate listing on the Main Board, with BNP Paribas, HSBC, and J.P. Morgan as joint sponsors. The group, which operates premium all-inclusive resorts under the Club Med brand, reported revenue of EUR 1.95 billion in 2025, up from EUR 1.86 billion in 2023, and adjusted EBITDA of EUR 390 million, with the margin rising to 20.2%. It currently operates 69 resorts worldwide and expects to expand to approximately 85 resorts by 2030. Proceeds from the listing will primarily fund global resort network expansion, vacation offering upgrades, and digital and AI capabilities, with the remainder used for capital structure optimization and operations. Chairman Xu Xiaoliang called the filing an important milestone for Fosun's tourism business.

Fosun International has received five awards from Corporate Governance Asia, including Asia's Best CEO honors for Co-CEOs Chen Qiyu and Xu Xiaoliang. The company also won the Sustainable Asia Award 2026, Best Environmental Responsibility Award, and Best Corporate Communications Award at the 16th Asian Excellence Award ceremony. The recognition highlights Fosun's strong financial performance, corporate governance, and ESG practices amid global economic transformation. Fosun's MSCI ESG rating has been upgraded to AAA, and it has maintained a Hang Seng Sustainability Rating of AA-, while also being included in S&P Global's Sustainability Yearbook 2026. The company continues to advance its sustainability commitments, including a target to peak carbon emissions by 2028 and achieve carbon neutrality by 2050.

Giantec Semiconductor, Deye Technology, and Yuyantang have submitted listing applications to the Main Board of the Hong Kong Stock Exchange. Giantec Semiconductor is a high-performance non-volatile memory chip design company, Deye Technology is a global manufacturer of solar and energy storage products, and Yuyantang is a private chain provider of traditional Chinese medicine healthcare services in China. Yonghe Medical expects net profit for the first half of the year to be no less than 70 million yuan, up no less than 150.9 percent year on year, with revenue expected to grow no less than 10.0 percent compared with the same period in 2025. Xipuni expects net profit for the first half to exceed 96 million yuan, up more than 70 percent year on year. Fosun International expects mid-term profit attributable to shareholders of the parent company to be approximately 1.5 billion to 1.8 billion yuan, up about 127 percent to 172 percent year on year.